Acta Medica Okayama 72巻 3号
2018-06 発行

R-mini CHP in ≥80-year-old Patients with Diffuse Large B-cell Lymphoma: A Multicenter, Open-label, Single-arm Phase II Trial Protocol

Miyata, Yasuhiko Department of Hematology, Nagoya Medical Center
Saito M. , Akiko Clinical Research Center, Nagoya Medical Center
Yano, Takahiro Department of Hematology, Tokyo Medical Center
Yoshida, Isao Department of Hemato-oncology, Shikoku Cancer Center
Suehiro, Youko Department of Hematology, Kyushu Cancer Center
Harada, Naoki Department of Hematology, Kyushu Medical Center
Nagai, Hirokazu Department of Hematology, Nagoya Medical Center
Publication Date
2018-06
Abstract
In very-elderly diffuse large B-cell lymphoma (DLBCL) patients, treatment intensities must be lowered due to the risks of comorbidities and organ function deterioration, and treatment outcomes are worse compared to younger patients. Very-elderly patients are often excluded from DLBCL clinical trials, and optimal treatments and dosages are not established. In this clinical trial, we examined the efficacy and safety of 6 courses of R-mini CHP therapy (cf., CHOP [cyclophosphamide, doxorubicin, vincristine, and prednisone]) in which vincristine is omitted to avoid the peripheral neuropathy that reduces elderly patients’ quality of life, as remission induction therapy in DLBCL patients aged≥80 years.
Document Type
Clinical Study Protocol
Keywords
rituximab
diffuse large B-cell lymphoma
open-label
single arm trial
Link to PubMed